Large UK study suggests HRT may reduce dementia risk when started during midlife

For years clinicians and patients treated hormone-replacement therapy (HRT) with caution after the early-2000s Women's Health Initiative (WHI) reported higher risks for outcomes including heart disease, stroke, breast cancer, and dementia. That trial mostly enrolled older women (average age about 63), many of whom were already years past menopause when they received HRT.

Researchers in the UK analyzed health records for more than 180,000 postmenopausal women and compared dementia diagnoses between HRT users and nonusers. Overall, HRT users had a modestly lower risk of developing dementia — roughly a 10% reduction. The pattern varied by age at initiation.

Women who began HRT between about 46 and 56 experienced the clearest association with reduced dementia risk. Women who started HRT at older ages showed at best no cognitive protection and possibly harm. This pattern supports the idea of a ''window of opportunity'' in midlife when hormone intervention may affect long-term brain health more positively than starting treatment later.

The WHI findings reshaped HRT prescribing and public opinion because most participants were older and the trial reported increased risks in several areas. Over subsequent decades, researchers questioned whether those results applied to women who take HRT earlier, during perimenopause or early postmenopause. The new UK analysis broadens the age range and aligns with a growing body of studies suggesting early HRT may benefit the heart, bones, and brain when used by symptomatic women at midlife.

This study is observational, not a randomized, placebo-controlled trial. That means it can identify associations but cannot prove HRT caused the lower dementia risk. Researchers and clinicians caution that the findings need replication and further study to separate the effects of HRT type, dose, delivery method (pills, patches, gels), and patient factors such as underlying health and timing relative to menopause.

This large UK study adds to evidence that HRT begun in the mid-40s to mid-50s may be associated with modestly lower dementia risk later in life. Because the data are observational, they should inform discussions with clinicians but not be taken as definitive proof. Ongoing and future randomized trials will be needed to confirm benefit, define optimal timing and regimens, and clarify safety for different patient groups.